Over the past decade many large randomized trials have been conducted in patients with
locally advanced or metastatic non-small cell lung cancer (NSCLC); however, no single …

Introduction Recent phase III studies in advanced non–small-cell lung cancer (NSCLC) have
demonstrated differential efficacy for pemetrexed according to NSCLC histology. The results …

Purpose: Platinum-based regimens represent the standard first-line treatment for non-small-
cell lung cancer (SNCLC). However, newer data have established a role for pemetrexed in …

Background The objective of this study was to evaluate the efficacy and safety of
pemetrexed plus cisplatin/carboplatin in locally advanced or metastatic non-small cell lung …

ABSTRACT Background and Objective: Pemetrexed plus platinum has shown efficacy as a
first‐line treatment for advanced non–small cell lung cancer (NSCLC), but little is known …

Introduction Recent pivotal phase III studies in patients with advanced non-small cell lung
cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with …

Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing
and the search for new active and safe drugs is warranted. The chemotherapeutic agent …

Background: Several pre-clinical and clinical studies suggest a potential predictive role of
epidermal growth factor receptor (EGFR) mutation in responsiveness to cytotoxic …

INTRODUCTION: The primary objectives of this study were to determine the recommended
dose of pemetrexed and carboplatin in patients with chemo-naive advanced non-small cell …

BACKGROUND The primary objectives of this study were to determine the efficacy and
tolerability of a pemetrexed‐carboplatin combination as first‐line therapy in patients with …